Parks, David A <br/><br/>
Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).  [electronic resource] 

 -  HIV clinical trials   
 - 160-7 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-4336 
<br/><br/><label>Standard No.: </label>10.1310/hct1003-160  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--administration & dosage<br/>Adult<br/>Anti-HIV Agents--administration & dosage<br/>Antiviral Agents--administration & dosage<br/>CD4 Lymphocyte Count<br/>Carbamates--administration & dosage<br/>Chromatography, High Pressure Liquid<br/>Deoxycytidine--administration & dosage<br/>Drug Combinations<br/>Emtricitabine<br/>Female<br/>Furans<br/>HIV Infections--blood<br/>HIV-1--drug effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Organophosphates--administration & dosage<br/>Organophosphonates--administration & dosage<br/>Prospective Studies<br/>RNA, Viral<br/>Ritonavir--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Tenofovir<br/>Viral Load